U.S. Food and Drug Administration Accepts Filing for Genentech’s Gazyva Targeting the Most Prevalent Form of Lupus
Genentech, a member of the Roche Group, has announced a major regulatory milestone in its efforts to expand treatment options for autoimmune diseases. The company confirmed that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for Gazyva (obinutuzumab) as a potential therapy for systemic lupus erythematosus (SLE). This acceptance marks an important step forward in the development of new therapies for a complex and often debilitating autoimmune condition that affects millions of people worldwide.
The regulatory submission is supported by compelling data from the Phase III ALLEGORY clinical trial, which demonstrated statistically significant and clinically meaningful improvements in disease outcomes among patients treated with Gazyva. With the application now formally under review, the FDA is expected to deliver its decision by December 2026, potentially paving the way for a new therapeutic option for individuals living with SLE. Notably, Gazyva is already approved in both the United States and the European Union for the treatment of lupus nephritis in adults, providing a strong foundation for its continued development in broader lupus indications.
Systemic lupus erythematosus is a chronic autoimmune disease characterized by widespread inflammation that can affect multiple organ systems, including the skin, joints, kidneys, heart, and brain. The disease is highly heterogeneous, meaning its symptoms and severity can vary significantly from one patient to another. Patients often experience unpredictable cycles of flares and remission, making disease management particularly challenging. Current treatment strategies frequently rely on immunosuppressive therapies and corticosteroids, which can carry significant long-term side effects. As a result, there remains a substantial unmet need for therapies that can effectively control disease activity while minimizing treatment-related toxicity.
Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development at Genentech, emphasized the importance of this milestone. He highlighted that the FDA’s acceptance of the sBLA brings the company closer to potentially delivering a highly effective new treatment option for people living with SLE. According to Dr. Garraway, Gazyva has the potential not only to improve disease control but also to increase the likelihood of achieving complete remission. Additionally, he noted that the therapy may help reduce patients’ dependence on long-term steroid use, which is a key goal in lupus management due to the adverse effects associated with chronic corticosteroid exposure.
The broader lupus community has also responded with cautious optimism to this development. Albert T. Roy, president and CEO of the Lupus Research Alliance, underscored the profound physical and emotional burden that SLE places on patients. He expressed hope that Gazyva could become a valuable addition to the treatment landscape, particularly given its potential to manage symptoms more effectively, increase rates of clinical remission, and reduce the frequency of debilitating disease flares. Such advancements could significantly improve quality of life for patients who often struggle with the unpredictable nature of the disease.
The clinical data supporting the sBLA were simultaneously presented at the SLEuro 2026, the 15th European Lupus meeting, and published in the prestigious The New England Journal of Medicine in March 2026. This dual dissemination underscores the scientific rigor and importance of the findings, as well as the broader interest within the medical community in advancing lupus treatment.
The Phase III ALLEGORY study serves as the cornerstone of the regulatory submission. The trial evaluated the efficacy and safety of Gazyva in combination with standard therapy compared to placebo plus standard therapy in patients with SLE. The primary endpoint of the study was the SLE Responder Index 4 (SRI-4) at 52 weeks, a widely used composite measure that assesses improvements in disease activity, symptoms, and overall physical condition.
Results from the study were highly encouraging. More than three-quarters (76.7%) of patients receiving Gazyva in combination with standard therapy achieved at least a four-point improvement in SRI-4 at 52 weeks. In contrast, only 53.5% of patients receiving placebo plus standard therapy reached this endpoint. This represents an adjusted difference of 23.1%, with a 95% confidence interval of 12.5 to 33.6, and a p-value of less than 0.001, indicating strong statistical significance. These findings suggest that Gazyva can deliver meaningful improvements in disease control for a substantial proportion of patients.
In addition to meeting its primary endpoint, the ALLEGORY study demonstrated consistent benefits across a range of key secondary endpoints. One such endpoint was the British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) response at 52 weeks, where Gazyva also showed superiority over placebo. The therapy further demonstrated its ability to support glucocorticoid reduction, with patients achieving and maintaining doses of 7.5 mg per day or less from week 40 through week 52. This is a particularly important outcome, as reducing steroid exposure is a critical objective in minimizing long-term treatment-related complications.
Another significant finding from the study was the reduction in disease flares among patients treated with Gazyva. Using the British Isles Lupus Assessment Group (BILAG) index to define flares, the study showed that patients receiving Gazyva plus standard therapy were significantly less likely to experience a flare through week 52 compared to those receiving placebo. The hazard ratio was 0.58, with a 95% confidence interval of 0.40 to 0.82 and a p-value of 0.002. This reduction in flare risk is clinically meaningful, as flares can lead to cumulative organ damage and long-term disability.
The study also provided compelling evidence of Gazyva’s ability to promote remission. At 52 weeks, the proportion of patients achieving remission as defined by the Definition of Remission in SLE (DORIS) criteria was more than doubled in the Gazyva group compared to placebo. Specifically, 33.8% of patients receiving Gazyva achieved remission, compared to 13.8% in the placebo group, representing an adjusted difference of 19.9%.
Similarly, the proportion of patients achieving Lupus Low Disease Activity State (LLDAS) was significantly higher in the Gazyva group, with 57.6% of patients reaching this milestone compared to 25.0% in the placebo group. These findings highlight the therapy’s potential to not only control disease activity but also to move patients toward sustained low disease activity or remission.
Importantly, the safety profile of Gazyva observed in the ALLEGORY study was consistent with its previously established safety characteristics. No new safety signals were identified, and the therapy was generally well tolerated. This is a crucial consideration for chronic conditions like SLE, where patients often require long-term treatment.
The implications of the ALLEGORY study extend beyond SLE. Data from the trial have also been submitted to the European Medicines Agency as part of a regulatory filing in Europe, reflecting the global potential of Gazyva in autoimmune disease management. Furthermore, ALLEGORY is one of four positive Phase III studies evaluating Gazyva across a range of immune-mediated diseases.
In addition to ALLEGORY, the REGENCY study demonstrated efficacy in lupus nephritis, while the INShore study evaluated the therapy in idiopathic nephrotic syndrome, and the MAJESTY study focused on primary membranous nephropathy. Together, these trials represent a growing body of evidence supporting the versatility and therapeutic potential of Gazyva across multiple disease indications driven by immune dysregulation.
This expanding clinical program aligns with Genentech’s broader strategy to advance innovation in immunology, particularly in diseases affecting the kidneys and rheumatological systems. By targeting key pathways involved in immune system dysfunction, therapies like Gazyva have the potential to address underlying disease mechanisms rather than simply managing symptoms.
The acceptance of the sBLA by the FDA is therefore not just a regulatory milestone, but also a reflection of the progress being made in understanding and treating complex autoimmune diseases. If approved, Gazyva could represent a significant advancement in the standard of care for SLE, offering patients a new option that combines efficacy, safety, and the potential for improved long-term outcomes.
As the FDA review process moves forward, the medical community will be closely watching for the agency’s decision. A positive outcome could usher in a new era of treatment for SLE, providing hope for patients who continue to face the challenges of this unpredictable and often life-threatening condition.
In the meantime, Genentech continues to build on its legacy of scientific innovation, leveraging its expertise in biologics and immunology to develop therapies that address unmet medical needs. The company’s work on Gazyva exemplifies this commitment, highlighting the potential of targeted therapies to transform the treatment landscape for autoimmune diseases.
Ultimately, the progress represented by the ALLEGORY study and the FDA’s acceptance of the sBLA underscores a broader shift in medicine toward more precise, mechanism-based treatments. For patients with SLE, this shift holds the promise of better disease control, fewer complications, and an improved quality of life—outcomes that have long been the goal of researchers, clinicians, and patient advocates alike.
About Gazyva
Gazyva® (obinutuzumab) is a humanized monoclonal antibody designed with a Type II anti-CD20 region, for direct B cell death and a glycoengineered Fc region, for higher binding affinity and increased antibody-dependent cellular cytotoxicity (ADCC). CD20 is a protein found on certain types of B cells. Gazyva is approved for adults with lupus nephritis in the US and EU. Gazyva is also approved in 100 countries for various types of hematological cancers.
About the ALLEGORY Study
ALLEGORY [NCT04963296] is a Phase III, randomized, double-blind, placebo-controlled, multicenter study, investigating the efficacy and safety of Gazyva® (obinutuzumab) compared with placebo in adults with systemic lupus erythematosus (SLE) on standard therapy. The study enrolled approximately 300 people, who were randomized 1:1 to receive Gazyva or placebo for up to one year (52 weeks), followed by an open-label period with Gazyva for up to 104 weeks. The primary endpoint is the percentage of people who achieve SLE Responder Index four at week 52.
About Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a potentially life-threatening autoimmune disease that affects more than three million people worldwide, and is rising. It is a chronic disease that causes inflammation in various parts of the body; for this reason it can affect multiple organ systems, especially the skin, joints and kidneys. As multiple organ systems are affected, it can cause varying symptoms, often taking two to six years for an accurate diagnosis. During this time, disease severity and organ damage, due to repeated flares of disease activity, typically worsens and quality of life declines.
Around half of people with SLE will develop lupus nephritis within five years of a lupus diagnosis. In lupus nephritis, the disease activity primarily affects the kidneys, posing a risk of kidney failure, where dialysis and transplant are the only treatment options.
There is a need for additional targeted therapies that can effectively control SLE disease activity and potentially delay or prevent the onset of lupus nephritis.
Source Link:https://www.businesswire.com/
